ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

Launched by M.D. ANDERSON CANCER CENTER · Mar 18, 2015

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called ONC201 for patients with certain types of leukemia or high-risk myelodysplastic syndrome (a blood disorder) that have either returned after treatment or have not responded to other therapies. The trial aims to find out the best dose of ONC201 and to understand its side effects. ONC201 works by blocking certain enzymes that cancer cells need to grow, which may help slow down or stop the cancer.

To participate in this trial, patients must be at least 18 years old and have a type of leukemia or myelodysplastic syndrome that has not responded to standard treatments. They should be in relatively good health, as measured by their ability to perform daily activities. Participants will receive ONC201 and will be monitored closely for any side effects and how well the treatment works. It's important to note that women who can become pregnant and men must follow specific guidelines to prevent pregnancy during the study. Overall, this trial offers hope for those facing difficult-to-treat blood cancers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • For Arms A, B, C, D, E, F patients must have relapsed or refractory acute leukemias or high-risk MDS for which no standard therapies are anticipated to result in a durable remission
• • Age \>= 18 years
• • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• • Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use acceptable contraceptive methods (abstinence, intrauterine device \[IUD\], oral contraceptive or double barrier device, such as a condom, diaphragm, or cervical/vault cap), for 16 weeks after the last dose of study drug, and must have a negative serum or urine pregnancy test within 1 week prior to beginning treatment on this trial; nursing patients are excluded; sexually active men must also use acceptable contraceptive methods for the duration of time on study and for at least 16 weeks after the last dose of study drug; pregnant and nursing patients are excluded because the effects of ONC201on a fetus or nursing child are unknown
• • Must be able and willing to give written informed consent
• • The interval from prior treatment to time of study drug administration should be at least 2 weeks for cytotoxic agents or at least 5 half-lives for noncytotoxic agents; if the patient is on hydroxyurea to control peripheral blood leukemic cell counts, the patient must be off hydroxyurea for at least 24 hours before initiation of treatment on this protocol; persistent clinically significant toxicities from prior therapy must not be greater than grade 1
• • Serum creatinine \< 2.0 mg/dl
• • Total bilirubin =\< 1.5 x the upper limit of normal (ULN) unless considered due to Gilbert's syndrome
• • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =\< 3 x the ULN unless considered due to organ leukemic involvement
• * Relapse \> 6 months since autologous or allogeneic stem cell transplantation provided:
• • No active graft-versus-host disease (GVHD \> grade 1)
• • No treatment with high dose steroids for GVHD (up to \>= 20 mg prednisolone or equivalent per day)
• • No treatment with immunosuppressive drugs with the exception of low dose cyclosporine and tacrolimus
• Exclusion Criteria:
• • Uncontrolled intercurrent illness including, but not limited to uncontrolled infection, symptomatic congestive heart failure (New York Heart Association class III and IV), uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• • Active heart disease including myocardial infarction within previous 3 months, symptomatic coronary artery disease, arrhythmias not controlled by medication, or uncontrolled congestive heart failure (New York Heart Association class III and IV)
• • Patients receiving any other standard or investigational treatment for their hematologic malignancy within past 2 weeks for cytotoxic agents or at least 5 half-lives for noncytotoxic agents
• • Subject has been diagnosed or treated for another malignancy within 3 years of enrolment, except in situ malignancy, or low-risk prostate, skin or cervix cancer after curative therapy
• • Known history of seropositive for human immunodeficiency virus (HIV) antibodies (HIV1 and HIV2), hepatitis C antibody (Hep C Ab) or a hepatitis B carrier (positive for hepatitis B surface antigen \[HBsAg\])
• • Active drug use or alcoholism
• • Known or active central nervous system (CNS) involvement by leukemia
• • White blood cell count more than 25 x 109/L prior to initiation of venetoclax